Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
27 Febbraio 2014 - 3:05PM
Marketwired
Stellar Biotechnologies to Present at the 26th Annual ROTH Capital
Growth Conference
PORT HUENEME, CA--(Marketwired - Feb 27, 2014) - Stellar
Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF)
(TSX-VENTURE: KLH), a company focused in the immunotherapy arena
with world-leading technology in Keyhole Limpet Hemocyanin (KLH)
protein, announced today that the Company will present at the 26th
Annual ROTH Capital Partners Growth Conference to be held March
9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point,
California.
Frank Oakes, President and CEO of Stellar Biotechnologies, will
present on Wednesday, March 12th at 11:00 AM PST (2:00 PM
EST). Members of Stellar's executive team will be available
for one-on-one meetings throughout the event. A link to the
webcast will be available on the Investor Relations portion of the
Company's website at
http://stellarbiotechnologies.com/investors/profile_presentations/.
Attendance at the conference is by invitation only and
interested investors should contact the conference organizers at
ROTH Capital. For more information about the conference or to
schedule a meeting with Stellar Biotechnologies management, please
contact your ROTH representative at 1-800-933-6830 or via e-mail at
conference@roth.com. Conference Website:
http://www.roth.com/main/page.aspx?PageID=7214
Stellar Presentation Details: Date and Time: March 12, 2014 @
11:00 AM PST (2:00 PM EST) Venue Location: The Ritz-Carlton, Laguna
Niguel in Dana Point, California. Presentation Room: Track 5, Salon
5 Stellar Presentation Webcast Link:
http://wsw.com/webcast/roth28/SBOTF
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-VENTURE: KLH) (OTCQB: SBOTF)
is the world leader in sustainable manufacture of Keyhole Limpet
Hemocyanin (KLH), an important immune-stimulating protein used in
wide-ranging therapeutic and diagnostic markets. KLH is both an
active pharmaceutical ingredient (API) in many new immunotherapies
(targeting cancer, infectious diseases, and immune disorders) as
well as a finished product for measuring immune status. Stellar
Biotechnologies is unique in its proprietary methods, facilities,
and KLH technology. We are committed to meeting the growing
demand for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based
active immunotherapies.
To receive regular updates, enter email at
http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base
www.KLHSite.org.
Forward Looking Statements There can be no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Readers should not place undue
reliance on such statements. Except in accordance with applicable
securities laws, the Company expressly disclaims any obligation to
update any forward-looking statements or forward-looking statements
that are incorporated by reference herein. This news release does
not constitute an offer to sell, or a solicitation of an offer to
buy any of the Company's securities set out herein in the United
States, or to, or for the benefit or account of, a U.S. Person or
person in the United States. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of these releases.
Grafico Azioni Stellar Biotechnologies, Inc. (TSXV:KLH)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Stellar Biotechnologies, Inc. (TSXV:KLH)
Storico
Da Gen 2024 a Gen 2025
